<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083936</url>
  </required_header>
  <id_info>
    <org_study_id>FET-PCNSL</org_study_id>
    <nct_id>NCT05083936</nct_id>
  </id_info>
  <brief_title>Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma</brief_title>
  <official_title>Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this imaging trial is to prospectively compare the usefulness of 18F-FDG&#xD;
      PET and 18F-FET PET in evaluating treatment response and predicting prognosis in patients&#xD;
      with central nervous system lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of target to background ratio between baseline, mid-therapy and end-of treatment PET in patients with primary central nervous system lymphoma</measure>
    <time_frame>20-40 minutes post injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1.5 year progression free survival</measure>
    <time_frame>18months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Patients With Suspected or Diagnosed Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>[18F]FET PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]FET</intervention_name>
    <description>Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor</description>
    <arm_group_label>[18F]FET PET</arm_group_label>
    <other_name>Fluoroethyl-L-tyrosine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible for participation in this trial, the subject must:&#xD;
&#xD;
          -  Be â‰¥ 19 years of age.&#xD;
&#xD;
          -  Patients diagnosed with central nervous system lymphoma by surgery/biopsy or suspected&#xD;
             of central nervous system lymphoma by anatomical imaging examination such as MRI.&#xD;
&#xD;
          -  Patients who have results or are planning to examine 18F-FDG PET in the above&#xD;
             patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subject must be excluded from participating in the trial if the subject fulfil any&#xD;
        single criteria described below:&#xD;
&#xD;
          -  Pediatric and adolescent patients under 19 years of age.&#xD;
&#xD;
          -  The patient is pregnant, is attempting to become pregnant, or is nursing&#xD;
             (breast-feeding) to children.&#xD;
&#xD;
          -  Patients with diagnosed or suspected lymphoma lesions in organs other than the cetral&#xD;
             nervous system.&#xD;
&#xD;
          -  Based on the investigator's judgement, if the patient makes it impossible to collect&#xD;
             complete data for a clinical trial due to personal or other reasons.&#xD;
&#xD;
          -  Patients who cannot stably have PET/CT due to claustrophobia, dyskinesia, anxiety&#xD;
             disorder, seizure, etc.&#xD;
&#xD;
          -  Based on the investigator's judgement, if the patient has a serious and/or&#xD;
             uncontrolled and/or unstable medical disease (e.g., congestive heart failure, acute&#xD;
             myocardial infarction, severe lung disease, chronic renal disease or chronic liver&#xD;
             disease, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Minyoung Oh, M.D.,Ph.D.</last_name>
    <phone>+82-2-3010-1447</phone>
    <email>my@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-Gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minyoung Oh, M.D.,Ph.D.</last_name>
      <phone>+82-2-3010-1447</phone>
      <email>my@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Minyoung Oh</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

